RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Summary

This first-in-human study will evaluate RVU120 (SEL120), a novel small molecule CDK8/19 inhibitor, in patients with Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (HR-MDS), in terms of selection of the recommended dose for further clinical development and assessment of safety, tolerability, preliminary anti-leukemic activity, as well as pharmacokinetic and pharmacodynamic profiles.

Timeline

Start

2019-09-04

Primary completion

2024-12-30

Completion

2024-12-30

Drugs

Indications